Kezdőlap・Részvénylista・Sana Biotechnology Inc

Sana Biotechnology Inc

Lezárt

SzektorEgészségügy

3.5 0.29

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.34

Maximum

3.5300000000000002

Fő mutatók
By Trading Economics
Bevétel	12M -47M
Egy részvényre jutó nyereség	-0.14
Munkavállalók	142
EBITDA	13M -45M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+188.24% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 7.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-76M 885M
Előző nyitás	3.21
Előző zárás	3.5

Hangulat hírek alapján

By Acuity

25%

75%

90 / 340 Rangsor szerint Healthcare

Sana Biotechnology Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 4. 20:05 UTC

Sana Biotechnology Inc shares are higher, reflecting strong performance amid a decline in crude oil prices, which may ease inflationary pressures.

2026. aug. 3. 19:46 UTC

Sana Biotechnology Inc is higher today, benefiting from a broader market rally, particularly in technology, despite earlier session pullbacks.

2026. júl. 31. 23:06 UTC

Sana Biotechnology Inc shares are lower in after-market hours, retracing from earlier gains. Broader market trends show mixed sentiment among major tech firms.

2026. júl. 30. 19:29 UTC

Sana Biotechnology Inc shares are higher today, recovering from earlier lows. The stock has shown an upward trend since Wednesday's close.

2026. júl. 29. 23:36 UTC

Sana Biotechnology Inc shares are higher in after-market hours, reflecting a slight increase since Wednesday's close amid routine market activity and broader volatility.

2026. júl. 28. 18:03 UTC

Sana Biotechnology Inc. shares are higher as biotechnology stocks advance, though they diverge from a recent trend of daily gains since Monday's close.

2026. júl. 27. 19:07 UTC

Sana Biotechnology Inc shares are higher today, continuing a rally since Friday. No specific news has been identified to explain the price movement.

2026. júl. 24. 18:26 UTC

Sana Biotechnology Inc. shares are trading lower amid broader market volatility, with no specific company news identified to explain the decline.

2026. júl. 22. 19:36 UTC

News

Sana Biotechnology has shifted focus to B-cell autoimmune disorders amid competition in oncology. Shares are higher since Tuesday, supported by rising crude oil prices.

2026. júl. 20. 17:56 UTC

Social Media

Sana Biotechnology Inc shares are lower, continuing a nine-session decline. Social media discussions raise skepticism about the timeline for its allogeneic cell therapies.

Társak összehasonlítása

Árváltozás

Sana Biotechnology Inc Előrejelzés

Célár

By TipRanks

188.24% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 9.8 USD 188.24%

Magas 16 USD

Alacsony 7 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Sana Biotechnology Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

Vétel

Tartás

Eladás

6 Wall Street elemző célárain alapulva a(z)Sana Biotechnology Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

90 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.